

Additional tables Well-being of the patient chapter Section Access to healthcare and medicine

We report on the effectiveness of our material nonfinancial topics by monitoring key performance indicators (KPI) and providing qualitative information. This overview contains additional non-audited data and non-audited information supplementing the Group Non-financial Report 2023.

Tables:

- Table 1: Cooperation with programs and initiatives: healthcare products market segment
- Table 2: Cooperation with programs and initiatives: healthcare services market segment
- Table 3: Exemplary list of social activities

Table 1

Cooperation with programs and initiatives: healthcare products market segment

Program/initiative	Goal/purpose	Type
AMR Industry Alliance	The AMR Industry Alliance is a coalition of over 100 biotechnology, diagnostics, generics, and research-based pharmaceutical companies and associations. The aim of the association is to offer sustainable solutions to curb antimicrobial resistance (AMR), which is increasingly threatening global health. The AMR Industry Alliance aims to achieve this by facilitating collaboration, reporting on industry contributions, and engaging with external stakeholders.	Industry association
International Generic and Biosimilar Association (IGBA)	The International Generic and Biosimilar Medicines Association (IGBA) represents global manufacturers of generic and biosimilar medicines. The goal of IGBA is to promote policies that enable sustainable access to high-quality, safe, and effective generic and biosimilar medicines worldwide. Its purpose includes advocating for regulatory frameworks that encourage competition, fostering international collaboration, and ensuring the availability of affordable alternatives to branded medicines, thereby contributing to global healthcare access.	Industry association
Medical Nutrition International Industry Group (MNI)	An international industry association representing the medical nutrition industry at an international level. The participating companies offer solutions for nutrition therapy: oral nutritional supplements (ONS), enteral tube feeding (nutrition via the gastrointestinal tract), and parenteral nutrition (intravenous nutrition). The association's members also include companies that	Industry association

	specialize in nutritional ingredients and medical devices.	
Medicines for Europe	<p>Medicines for Europe represents the pharmaceutical companies that manufacture and supply the majority of medicines in Europe. The industry association thus also represents the generics, biosimilar, and value-added industries.</p> <p>The goal is to improve the health and well-being of European patients through better access to high-quality medicines.</p> <p>The portfolio of Medicines for Europe members covers 80% of therapeutic areas and can thus help to ensure the sustainability of European healthcare systems for future generations.</p>	Industry association
Association for Accessible Medicines	<p>The Association for Accessible Medicines (AAM) and its Biosimilar Council division is a trade association representing generic and biosimilar pharmaceutical companies in the United States. Its primary goal is to improve access to safe, effective, and affordable medicines. The association works towards fostering a competitive market for generic and biosimilar drugs, advocating policies that enhance patient access, and promoting the economic sustainability of the pharmaceutical industry. AAM aims to ensure a robust and diverse pharmaceutical marketplace that benefits both patients and healthcare providers through the availability of more affordable treatment options.</p>	Industry association
Biosimilars Forum	<p>The goal of the forum is to raise awareness of the benefits of biosimilars for patients, medical professionals, and national healthcare systems. It provides an opportunity for companies developing biosimilars for the United States to work together and with other key stakeholders on topics instrumental to biosimilars and patient care. The Biosimilars Forum collaborates with various partners to help improve awareness of and access to biopharmaceutical generics. The cooperation with Fresenius Kabi ended at the end of 2023.</p>	Industry association
action medeor	<p>This non-governmental organization provides low-cost medical aid by buying large quantities and delivers medical aid to disaster areas. Fresenius Kabi supports the organization in some situations with product donations.</p>	Public organization
Spanish Association of Biosimilar Medicines	<p>The Spanish Association of Biosimilar Medicines (BioSim), is a non-profit organization whose aim is to welcome and represent all pharmaceutical companies established in Spain that research, develop, produce and/or market biosimilar medicines.</p>	Industry association
Spanish Bioindustry Association	<p>The Spanish Bioindustry Association (AseBio) brings together and represents the interests of companies, associations, foundations, universities, and technology and research centers that work in the field of biotechnology in Spain.</p>	Industry association

Table 2

Cooperation with programs and initiatives: healthcare services market segment

Program/initiative	Goals/purpose	Type
Aktionsbündnis Patientensicherheit (Action Alliance for Patient Safety)	Aktionsbündnis Patientensicherheit is committed to safe healthcare and is dedicated to the research, development, and dissemination of suitable methods. Helios Germany is a member of the Action Alliance and part of the organization's interdisciplinary and multi-professional working and expert groups. The working groups meet regularly and publish their results in the form of recommendations for action, patient information, and publications, which are made available free of charge to all institutions in the German healthcare system, as well as patients and their relatives.	Public organization
DIGEM – a documentation system for community nurses	Fresenius Vamed developed software for the Austrian project Community Nurses (CNs), which supports nursing documentation: DIGEM (Digital Health Management) is already being used by around 40 CNs in Austria. The project was commissioned by the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection and the European Commission and is supported by Gesundheit Österreich GmbH. Its goal is to use CNs to create low-threshold, needs-oriented care close to the population at community level.	Public organization
Stay Healthy (Fundación Quirónsalud)	Awareness-raising campaign aimed at schools and young people. Experts from the Helios Spain Foundation explain the benefits of healthy habits to the target group and draw attention to the main health risks. In the reporting year, around 90,000 young people were reached in more than 1,000 schools.	Private organization
Fundación Quirónsalud	International cooperation with doctors who participate in or lead charitable projects. The work of the doctors and the financial support of the institutions (€10,000) enabled 24 projects to be supported in the reporting year.	Private organization
Fundación Quirónsalud	Patients can receive subsidies for medical care via the foundation if they have no financial resources. This is made possible by, among other things, an agreement with the energy company Naturgy. The energy savings resulting from the solar systems installed in Helios Spain's hospitals are donated to patients.	Private organization
Fundación Recover	The foundation focuses its efforts on improving the medical infrastructure in 11 sub-Saharan African countries (including Ethiopia, Burkina Faso, Cameroon and Chad), for example by providing medical equipment and medicines to enable treatment, supporting local medical staff, and promoting medical training. The foundation also has access to a network of non-medical volunteers. Helios Spain mainly supports Fundación Recover through donations.	Private organization

Table 3

Exemplary list of social activities

Program/initiative	Further information
Das Deutsche Rote Kreuz and the Fresenius Group	In 2023, Fresenius donated €500,000 to the German Red Cross to support the people affected by the earthquake in Morocco and the flood disaster in Libya.
KabiCare from Fresenius Kabi	KabiCare® is a self-developed support program for training and information services for healthcare professionals and patients: it was developed to support people living with a chronic disease, e. g., cancer or inflammatory diseases, who are being treated with a biosimilar product from Fresenius Kabi.
Americares in cooperation with Fresenius Kabi	In the United States, Fresenius Kabi has a more than 10-year relationship with Americares, a health-focused relief and development organization that responds to people affected by poverty or disaster with life-changing medicine, medical supplies, health services, and programs. Fresenius Kabi does this through financial support and in-kind (product) donations for missions in both the United States and internationally. Further, Fresenius Kabi USA participates in charitable fundraising and awareness activities to support a variety of health-related causes, including breast cancer, AIDS blood donation, sickle cell disease, and postpartum mental health.
Tulipe in cooperation with Fresenius Kabi	In France, Fresenius Kabi works together with Tulipe for donations in kind. This non-profit organization acts as an interface between the pharmaceutical industry and local associations. It pools donations from healthcare companies and thus helps to respond as quickly as possible to the urgent needs of people in distress, acute health crises, natural disasters and conflicts.
Starter program in cooperation with Fresenius Kabi	In Canada, the business segment also provides urgent anticoagulation treatment for out-of-hospital patients through the starter program (biosimilar to enoxaparine). They are provided with a free pack, which in Canada is equivalent to 5–10 days of treatment. The Compassionate Program extends ongoing anticoagulation therapy to patients without insurance coverage or financial resources and provides free medication for the entire duration of treatment.
JUMPstart in collaboration with Fresenius Kabi	JUMPstart is Fresenius Kabi's education and research program to help the next generation of clinical experts create high-quality research projects. Beyond providing education on effective study design and mentorship from expert senior researchers, the program cultivates an international community of researchers committed to advancing clinical nutrition therapy. There are two global programs: while JUMPstart Clinical Nutrition focuses on chronically and critically ill patients, JUMPstart Renal Nutrition Therapy focuses on patients with chronic kidney disease. The JUMPstart Clinical Nutrition grant of €250,000 was awarded at the European Society for Clinical Nutrition and Metabolism (ESPEN) Congress in 2023 to Dr. Zheng Yi Lee, Malaysia, who is investigating the role of fish oil-supplemented nutrition in critically ill patients. The JUMPstart Renal Nutrition Therapy grant of €100,000 was awarded to Dr. Elena Cuiban, Romania, for the impact of a ketoanalog-supported and protein-reduced diet in patients with chronic kidney disease and renal osteodystrophy.
United for Clinical Nutrition founded by Fresenius Kabi	To overcome hospital malnutrition in countries around the world, in 2014 Fresenius Kabi established the initiative United for Clinical Nutrition. This multinational initiative seeks to reduce the prevalence of this condition through education, data collection, and clinical assessment in selected geographical regions. To this end, dedicated clinical projects and awareness campaigns have been tailored for Latin America (since 2014), Asia (since 2017), and Europe (since 2019). Its mission is to improve medical nutrition therapy and quality of life with a strong focus on better patient outcomes across the region. As part of the United for Clinical Nutrition initiative, Fresenius Kabi first announced the Parenteral Nutrition Research Grant Latin America (LAM Grant) in 2018 to promote research aimed at improving nutritional care of hospitalized adult patients in Latin America. In the reporting year, the research grant was awarded for the third time. It was awarded to a project seeking to investigate the use of supplemental parenteral nutrition for affected patients in critical situations.